MiMedx Group (NASDAQ:MDXG) Announces Earnings Results

MiMedx Group (NASDAQ:MDXG) released its earnings results on Wednesday. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05, FiscalAI reports. The firm had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a return on equity of 30.61% and a net margin of 11.60%.

Here are the key takeaways from MiMedx Group’s conference call:

• MiMedx reported record 2025 results — full‑year net sales of $419M (+20%), Q4 net sales of $118M (+27%), adjusted EBITDA ~$106M and a net cash balance near $148M, strengthening profitability and liquidity.
• The Medicare reimbursement reset (price cap ~$127/cm²) and WISeR prior‑auth implementation have caused near‑term disruption, lower ASPs and slower wound volumes; management guides 2026 revenue of $340–360M with adjusted EBITDA in the mid‑to‑high teens.
• The surgical franchise is a clear growth driver — surgical sales grew ~25% in Q4 and 20% for the year, supported by increased commercial resources, new launches like AMNIOFIX Thyroid Shield, and recently licensed complementary surgical products.
• Strong capital flexibility: the company holds substantial cash and the board authorized a $100M share repurchase program over two years while remaining open to disciplined M&A to accelerate strategy.
• Clinical evidence push: the EPIEFFECT randomized controlled trial is nearly fully enrolled with results and publications expected soon, and an RCT for CHORIOFIX is planned, reinforcing the company’s evidence‑based positioning.

MiMedx Group Trading Down 0.3%

Shares of MDXG traded down $0.01 during midday trading on Friday, hitting $4.93. 677,313 shares of the stock were exchanged, compared to its average volume of 995,344. The firm has a market cap of $729.69 million, a P/E ratio of 15.42 and a beta of 1.59. MiMedx Group has a 52-week low of $4.79 and a 52-week high of $8.46. The stock has a fifty day simple moving average of $5.74 and a 200 day simple moving average of $6.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds have recently modified their holdings of MDXG. Royal Bank of Canada raised its holdings in MiMedx Group by 1.4% in the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after acquiring an additional 13,629 shares during the period. AQR Capital Management LLC increased its holdings in shares of MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in MiMedx Group during the 1st quarter worth $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after acquiring an additional 596,016 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDXG has been the topic of a number of recent research reports. Lake Street Capital dropped their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. UBS Group set a $10.00 target price on MiMedx Group in a research note on Monday. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Mizuho cut their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Finally, Citizens Jmp started coverage on shares of MiMedx Group in a research report on Monday. They set a “market outperform” rating and a $10.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, MiMedx Group presently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.